🏛️ Verified NIH Record • Updated 2026-07-27

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (NCT07022483)

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Daiichi Sankyo

🩺 Plain-English Summary (8th-Grade Level)

This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.

Who can join: Review the eligibility criteria below.

Location: Broward Health Medical Center — Fort Lauderdale, Florida

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (75 Sites)

Showing the first 25 of 75 sites.

  • Broward Health Medical Center — Fort Lauderdale, Florida
  • Miami Cancer Institute — Miami, Florida
  • Mount Sinai Medical Center — Miami Beach, Florida
  • Parkview Research Center — Fort Wayne, Indiana
  • Trials365 LLC — Shreveport, Louisiana
  • FirstHealth of the Carolinas, Inc. — Pinehurst, North Carolina
  • University of Cincinnati Physicians Group, LLC — Cincinnati, Ohio
  • Avera Medical Group Gynecologic Oncology Sioux Falls — Sioux Falls, South Dakota
  • Texas Oncology, P.A. - Tyler — Sioux Falls, South Dakota
  • Texas Oncology San Antonio Medical Center — San Antonio, Texas
  • Hospital Italiano de Buenos Aires — Ciudad Autonoma Buenos Aires,
  • Sanatorio Allende Cerro — Córdoba,
  • Centro de Investigaciones Medicas Mar del Plata — Mar del Plata,
  • Instituto de Oncologia de Rosario — Rosario,
  • CER San Juan Centro Polivalente de Asistencia e Inv. Clinica — San Juan,
  • Biocenter — Concepción,
  • Centro de Estudios Clinicos SAGA — Santiago,
  • Centro de Investigaciones Clinicas de la Universidad Catolica — Santiago,
  • Beijing Cancer Hospital — Beijing,
  • The First Hospital of Jilin University — Changchun,
  • West China Second University Hospital, Sichuan University — Chengdu,
  • Obstetrics and Gynecology Hospital Affiliated to Zhejiang University School of Medicine — Hangzhou,
  • Zhejiang Cancer Hospital — Hangzhou,
  • Cancer Hospital of Shandong First Medical University — Jinan,
  • Linyi Cancer Hospital — Linyi,

📞 Contact the Study Coordinator

Phone: (908) 992-6400

Email: CTRinfo_us@daiichisankyo.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Endometrial Cancer

Explore by condition: All Endometrial Cancer clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗